Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MasterCard Inc (MA) vs Revvity Inc (RVTY) Price & Performance

MasterCard IncTrade
Revvity IncTrade

Price performance (Past 24H)

Key statistics

MasterCard Inc vs Revvity Inc — how do they compare? MasterCard Inc trades at $583.74 (market cap $503.50B), while Revvity Inc trades at $153.88 (market cap $16.98B). The key difference: MasterCard Inc is far larger — about 29.7× Revvity Inc's market cap, and MasterCard Inc pays the higher dividend (0.61%). Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and Revvity Inc for 12 Days on average.

MARVTY
Market Cap
$503.50B$16.98B
Volume
3,390,8591,456,900
Sector
FinancialsHealth
52-Week High
$599.86$157.36
52-Week Low
$471.55$82.26
Typical Hold Time
134 Days12 Days
Enterprise Value
$516.53B$19.30B
Dividend Yield
0.61%0.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MasterCard Inc

Mastercard (MA) trades at $570.06, up 0.61% with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $32.79B in 2025 with impressive 46.34% net margins, though valuation multiples remain elevated with P/E at 31.61. Recent institutional buying activity and positive analyst coverage support the upward trend.

Mastercard presents a compelling growth story with expanding global payment volumes and digital transformation initiatives. The primary investment thesis centers on continued market share gains and margin expansion, though risks include payment industry disruption from stablecoins and elevated valuation multiples requiring sustained high growth. Analyst consensus targets $666.67 suggest 17% upside potential from current levels.

Revvity Inc

Revvity (RVTY) trades at $154.33, up 0.48% on the day and near its 52-week high of $158.28. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and positive analyst upgrades reflect solid fundamentals. Key developments include the launch of a new Type 1 diabetes screening kit in Europe and the acquisition of Human Cell Design to bolster metabolic disease research, signaling growth in diagnostics and life sciences.

The outlook remains positive given consistent earnings outperformance and strategic expansions, though rich valuation multiples pose a risk if growth moderates. Investors face near-term headwinds from margin pressures in China and elevated P/E ratios, but institutional accumulation and a lack of sell ratings support a constructive bias for long-term holders.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

MA
63% Buy37% Sell
Avg holding period · 134 Days
RVTY

No sentiment data available yet.

Top news

Latest headlines on both assets

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA →

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →